Chemotherapeutic agents for the treatment of metastatic breast
cancer: An update

J 2018

Chemotherapeutic agents for the treatment of metastatic breast cancer: An update

ABOTALEB, Mariam; Peter KUBATKA; Martin CAPRNDA; Elizabeth VARGHESE; Barbora ZOLAKOVA et. al.

Základní údaje

Originální název

Chemotherapeutic agents for the treatment of metastatic breast cancer: An update

Autoři

ABOTALEB, Mariam; Peter KUBATKA; Martin CAPRNDA; Elizabeth VARGHESE; Barbora ZOLAKOVA; Pavol ZUBOR; Radka OPATRILOVA; Peter KRUŽLIAK; Patrik STEFANICKA a Dietrich BUSSELBERG

Vydání

BIOMEDICINE & PHARMACOTHERAPY, Paris, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, 0753-3322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.743

Kód RIV

RIV/00216224:14110/18:00102919

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.biopha.2018.02.108

UT WoS

000429586400054

EID Scopus

2-s2.0-85042646206

Klíčová slova anglicky

Metastatic breast cancer; Chemotherapy; Efficacy; Toxicity; Resistance; Antimetabolites; Immunologic therapy; Hormonal/endocrine therapy; DNA alkylating agents; Ion modulators; Antimitotic agents

Štítky

14110121, EL OK, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 13:43, Soňa Böhmová

Anotace

V originále

Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.

Citovat

ABOTALEB, Mariam; Peter KUBATKA; Martin CAPRNDA; Elizabeth VARGHESE; Barbora ZOLAKOVA; Pavol ZUBOR; Radka OPATRILOVA; Peter KRUŽLIAK; Patrik STEFANICKA a Dietrich BUSSELBERG. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. BIOMEDICINE & PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, roč. 101, MAY 2018, s. 458-477. ISSN 0753-3322. Dostupné z: https://doi.org/10.1016/j.biopha.2018.02.108.

@article{1419758,
   author = {Abotaleb, Mariam and Kubatka, Peter and Caprnda, Martin and Varghese, Elizabeth and Zolakova, Barbora and Zubor, Pavol and Opatrilova, Radka and Kružliak, Peter and Stefanicka, Patrik and Busselberg, Dietrich},
   article_location = {Paris},
   article_number = {MAY 2018},
   doi = {https://doi.org/10.1016/j.biopha.2018.02.108},
   keywords = {Metastatic breast cancer; Chemotherapy; Efficacy; Toxicity; Resistance; Antimetabolites; Immunologic therapy; Hormonal/endocrine therapy; DNA alkylating agents; Ion modulators; Antimitotic agents},
   language = {eng},
   issn = {0753-3322},
   journal = {BIOMEDICINE & PHARMACOTHERAPY},
   title = {Chemotherapeutic agents for the treatment of metastatic breast cancer: An update},
   volume = {101},
   year = {2018}
}

TY  - JOUR
ID  - 1419758
AU  - Abotaleb, Mariam - Kubatka, Peter - Caprnda, Martin - Varghese, Elizabeth - Zolakova, Barbora - Zubor, Pavol - Opatrilova, Radka - Kružliak, Peter - Stefanicka, Patrik - Busselberg, Dietrich
PY  - 2018
TI  - Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
JF  - BIOMEDICINE & PHARMACOTHERAPY
VL  - 101
IS  - MAY 2018
SP  - 458-477
EP  - 458-477
PB  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
SN  - 07533322
KW  - Metastatic breast cancer
KW  - Chemotherapy
KW  - Efficacy
KW  - Toxicity
KW  - Resistance
KW  - Antimetabolites
KW  - Immunologic therapy
KW  - Hormonal/endocrine therapy
KW  - DNA alkylating agents
KW  - Ion modulators
KW  - Antimitotic agents
N2  - Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.
ER  -

ABOTALEB, Mariam; Peter KUBATKA; Martin CAPRNDA; Elizabeth VARGHESE; Barbora ZOLAKOVA; Pavol ZUBOR; Radka OPATRILOVA; Peter KRUŽLIAK; Patrik STEFANICKA a Dietrich BUSSELBERG. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. \textit{BIOMEDICINE \&{}amp; PHARMACOTHERAPY}. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, roč.~101, MAY 2018, s.~458-477. ISSN~0753-3322. Dostupné z: https://doi.org/10.1016/j.biopha.2018.02.108.

Přehled o publikaci